Vanda Pharma (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Wednesday, 2026-02-11. Here’s what investors need to know before the announcement.
Analysts estimate that Vanda Pharma will report an earnings per share (EPS) of $-1.67.
The market awaits Vanda Pharma’s announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It’s important for new investors to understand that guidance can be a significant driver of stock prices.
Earnings Track Record
During the last quarter, the company reported an EPS beat by $0.02, leading to a 20.15% drop in the share price on the subsequent day.
Here’s a look at Vanda Pharma’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.40 | -0.34 | -0.02 | -0.14 |
| EPS Actual | -0.38 | -0.46 | -0.50 | -0.08 |
| Price Change % | -20.00 | -2.00 | -4.00 | -6.00 |
Stock Performance
Shares of Vanda Pharma were trading at $7.51 as of February 09. Over the last 52-week period, shares are up 58.11%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Insights Shared by Analysts on Vanda Pharma
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Vanda Pharma.
The consensus rating for Vanda Pharma is Buy, based on 4 analyst ratings. With an average one-year price target of $15.88, there’s a potential 111.45% upside.
Peer Ratings Comparison
The analysis below examines the analyst ratings and average …